The immediate question is simple enough to fit on a bottle label. Should pregnant women avoid acetaminophen, commonly sold as Tylenol, because of possible neurodevelopmental harm to the child? The available facts in this news cycle point in one direction. Scientists conducted a study examining the relationship between acetaminophen and autism. The study found no link. It is not the first study to find no association. Yet after Donald Trump made public statements warning about Tylenol, usage among pregnant women decreased.
That sequence should concern anyone who cares about public health, institutional credibility, and the long record of how societies learn, and mislearn, about medicine in pregnancy. The strongest case for avoidance is not frivolous. Pregnancy medicine has a grim archive. The modern cautionary tale is thalidomide, the drug once marketed as safe for pregnant women and later exposed as catastrophic. It is therefore tempting to say that where unborn children are concerned, even a potential neurodevelopmental risk should trigger a broad warning. Better to forgo a pain reliever than repeat a historical disaster.
That instinct deserves respect. It is grounded in history, not hysteria. But history, properly read, cuts the other way here.
The first lesson of medical history is not merely that some assurances of safety proved wrong. It is that durable public guidance must rest on disciplined evidence, careful specification of risk, and institutional restraint. Panic has its own casualties. So does vague precaution. Once public figures begin treating every unresolved question as proof of danger, medicine for pregnant women collapses into a regime of rumor, avoidance, and second guessing. That pattern has precedent too, and it is not a good one.
Consider the actual claim in dispute. The resolution says pregnant women should avoid acetaminophen due to potential neurodevelopmental risks. The fact sheet, however, gives us one concrete neurodevelopmental concern under examination, autism, and tells us the study found no link. Not only that, it is not the first null finding. The strongest opposing argument in the debate seized on an important semantic point: no link to autism is not the same as no neurodevelopmental risk whatsoever. True enough. A study on one outcome does not magically eliminate every conceivable concern.
But public advice is not made by piling hypotheticals atop one another until ordinary life becomes impossible. There is no medicine, no food, no activity, and indeed no pregnancy itself, that can satisfy a rule of zero theoretical risk. The burden is on those urging avoidance to show more than possibility in the abstract. They must show some concrete evidentiary basis strong enough to outweigh the known benefits of acetaminophen as a common treatment for pain and fever. On the facts provided here, that showing has not been made.
This is where the rhetoric of the precautionary principle often becomes historically unserious. The principle has its place, especially when evidence of harm is emerging and exposure is hard to reverse. But in public health, precaution cannot mean issuing severe behavioral guidance every time science has not disproved every member of a broad category. If that became the rule, pregnant women would be left with a shrinking circle of acceptable remedies and an expanding burden of anxiety. We have seen that pattern before. Women are told to avoid first, ask questions later, while evidence lags, and the result is not always safer pregnancy. Sometimes it is merely more untreated pain, more untreated fever, and more confusion.
The fact sheet itself hints at this practical cost. Tylenol usage among pregnant women decreased after Trump's statements. That is not an impressive act of decentralized wisdom. It is a warning flare about how quickly unsupported claims can alter medical behavior. The issue is not Trump as an individual, except insofar as his intervention illustrates an old constitutional and civic problem: when charismatic authority competes with expert institutions, the public often receives heat without light. American history is full of episodes in which political theater outran evidentiary process. Those episodes rarely age well.
There is also a deeper institutional point. Medicines in pregnancy are already governed by an unusually conservative culture for understandable reasons. That caution is part of our inherited system. But the endurance of that system depends on discrimination, not maximalism. Institutions keep legitimacy by distinguishing between demonstrated harm, unresolved inquiry, and disproven alarm. If every unresolved question produces a practical taboo, then repeated studies finding no association cease to matter. At that point, evidence is no longer being weighed. It is being politely ignored.
The opposing side in this debate made one more argument worth taking seriously. It suggested that reduced acetaminophen use could function as a kind of natural experiment, allowing us to observe what happens when exposure falls. There is a kernel of descriptive truth there. Human behavior does generate data. But as a normative matter, one should recoil from celebrating misinformation because it accidentally rearranges the treatment choices of pregnant women. Public health should not conduct itself by shrugging at politically induced fear and calling the result informative.
Nor should we accept a bait and switch in the wording. The resolution says women should avoid acetaminophen. Avoid is a strong recommendation. It is not the same as use judiciously, discuss with a doctor, or take the lowest effective dose when needed. A historian's instinct is to pay close attention to the force of institutional language. Once the advice becomes avoid, ordinary readers hear unsafe. That is a serious claim, one that requires more than the observation that science has not refuted every imaginable theory.
What, then, should responsible guidance say? It should say exactly what the current record supports. Recent research found no link between acetaminophen use in pregnancy and autism. This is consistent with prior studies. Pregnant women should make medication decisions with clinicians based on actual symptoms, dose, duration, and alternatives, not on broad public warnings untethered from evidence. If future research identifies a specific neurodevelopmental risk, institutions should say so plainly and revise guidance accordingly. That is not complacency. It is how trustworthy systems work.
The long record counsels neither reckless reassurance nor indiscriminate alarm. It counsels proportion. Acetaminophen is not thalidomide merely because both are medications taken during pregnancy. Historical analogies are useful only when they clarify relevant similarities, not when they flatten all distinctions into dread. Here, the better analogy is to the many recurring episodes in which public fear raced ahead of the evidence and pregnant women bore the cost.
So the resolution should be rejected. Pregnant women should not be told to avoid Tylenol because of speculative neurodevelopmental risks when the concrete evidence presented in this case shows no link to autism, and when repeated studies have reached the same conclusion. The proper historical lesson is not to sanctify uncertainty. It is to govern it, carefully, institutionally, and with respect for the difference between possibility and proof.